[1]李江 徐斌 乔治 谭龙旺.强脊方对强直性脊柱炎患者Th17细胞及相关因子IL-6、IL-23影响的临床研究[J].陕西中医药大学学报,2022,(01):088-92.[doi:10.13424/j.cnki.jsctcm.2022.01.019]
　LI Jiang XU BinQIAO Zhi TAN Longwang.Clinical Study on The Effect of Qiangji Recipe on Th17 Cells and Related Factors IL-6 and IL-23 in Patients with Ankylosing Spondylitis[J].Journal of Shaanxi University of Traditional Chinese Medicine,2022,(01):088-92.[doi:10.13424/j.cnki.jsctcm.2022.01.019]
点击复制

强脊方对强直性脊柱炎患者Th17细胞及相关因子IL-6、IL-23影响的临床研究
分享到：

《陕西中医药大学学报》[ISSN:2096-1340/CN:61-1501/R]

卷:
期数:
2022年01期
页码:
088-92
栏目:
论著
出版日期:
2022-02-01

文章信息/Info

Title:
Clinical Study on The Effect of Qiangji Recipe on Th17 Cells and Related Factors IL-6 and IL-23 in Patients with Ankylosing Spondylitis
文章编号:
2096-1340(2022)01-0088-05
作者:
李江1 徐斌1 乔治2 谭龙旺1
1.陕西中医药大学附属医院，陕西 咸阳 712000;
2.西安市第五人民医院，陕西 西安 710000
Author(s):
LI Jiang1 XU Bin1QIAO Zhi2 TAN Longwang1
1.Affiliated Hospital of Shaanxi University of traditional Chinese medicine,Shaanxi Xianyang 712000,China；
2.Xian Fifth Peoples Hospital,Xian 710000,China
关键词:
关键词：强直性脊柱炎; Th17细胞; 中药; IL-6、IL-23
Keywords:
Key words： Ankylosing spondylitis; Th17 cells; Traditional Chinese medicine; IL-6、IL-23
分类号:
R289
DOI:
10.13424/j.cnki.jsctcm.2022.01.019
文献标志码:
A
摘要:
摘 要：目的 观察杨毓华教授验方强脊方治疗强直性脊柱炎疗效，以及对AS患者Th17细胞（T helpcell 17,Th17）及相关因子IL6、IL-23的影响。方法 患者分为验方中药组与柳氮磺嘧啶对照组，分别用药治疗2月。对中药组和对照组所有患者治疗前后进行强直性脊柱炎疾病活动度评分，C反应蛋白、血沉、HLA-B27检测，观察两组患者临床疗效。对所有病例治疗前进行抽血采样，流式细胞术检测Th17细胞数量；酶联免疫吸附法相关细胞因子IL-6、IL-23。治疗2月后再次进行抽血采样，组间进行标本对比分析。结果 治疗前后两组患者各项指标及Th17细胞数量均明显下降（P<0.05)，并且两组之间无明显差异（P>0.05）。结论 杨毓华教授验方强脊方可以减少AS患者Th17细胞及相关因子IL-6、IL-23，从而起到治疗作用，其疗效与柳氮磺嘧啶无明显差异。
Abstract:
Abstract： Objective To observe the efficacy of Professor YANG Yuhuas prescription Qiangji formula in the treatment of ankylosing spondylitis (AS) and its effect on Th17 cells and related factors IL-6 and IL-23 in patients with AS.Methods Patients were divided into the prescription traditional Chinese medicine group and the sulfasalazine control group,which were treated for 2 months respectively.All patients in the traditional Chinese medicine group and the control group were scored for disease activity of ankylosing spondylitis before and after treatment (ASDAS),Creactive protein,ESR and HLAB27 were detected to observe the clinical efficacy of the two groups.Blood samples were taken from all cases before treatment,and the number of Th17 cells was detected by flow cytometry；enzymelinked immunosorbent assay (ELISA) related cytokines IL-6 and IL-23.Blood samples were taken again after 2 months of treatment,and samples were compared and analyzed between groups.Results All indexes and the number of Th17 cells in the two groups decreased significantly before and after treatment (P<0.05),And there was no significant difference between the two groups (P>0-05).Conclusion Professor YANG Yuhuas prescription Qiangji recipe can reduce Th17 cells and related factors IL-6 and IL-23 in patients with AS,so as to play a therapeutic role,and its curative effect is not significantly different from that of sulfasalazine.

参考文献/References:

［1］Park H，Li Z，Yang XO，et al.A distinct Lineage of CD4 T cells regualate tissue inflammation by producing interleukin 17［J］.Nat Immuno1，2005，6(11):1133-1141.
［2］van der Linden S，Valkenburg HA，Cats A.Evaluation of diagnostic criteria for ankylosing spondylitis.A proposal for modification of the New York criteria［J］.Arthritis Rheum，1984，27(4)：361-368.
［3］Curotto de，Lafaille MA，Lafaille JJ.CD4(+)regulatory T cells in autoimmunity and allergy［J］.Curr Opin Immunol 2002，14:771-778.
［4］Bacchetta R，Gregori S，Roncarolo MG.CD4+ regulatory T cells:mechanisms of induction and effector function［J］.Autoimmun Rev，2005，4(8):491-496.
［5］梅杨.强直性脊柱炎患者外周血Th17/Treg细胞失衡研究［D］.合肥：安徽医科大学，2011.
［6］王翠玲，李开智，崔文.强直性脊柱炎患者外周血Th1，Th17，Treg细胞含量及相关细胞因子表达水平研究［J］.慢性病学杂志，2018，19(9):1154-1156，1160.
［7］王亚芳，王梅，宋爱凤.强直性脊柱炎患者外周血Th17/Treg平衡状态对疾病状况的评估价值［J］.国际检验医学杂志，2020，41(7):842-845.
［8］李文清.强直性脊柱炎患者外周血miR155表达及Th17/Treg平衡的关系［J］.山西医科大学学报，2019，50(2):235-240.
［9］AlvaradoSanchez B，HernandezCastro B，PortalesPerez D，et al.Regulatory T cells in patients with systemic lupus erythematosus［J］.J Autoimmun，2006，27:110-118.
［10］Roncarolo MG，Bacchetta R，Bordignon C，et al.Type 1 T regulatory cells［J］.Immunol Rev，2001，182(1):68-79.
［11］刘小莉，张红梅，唐敏，等.不同疾病分期强直性脊柱炎患者外周血DKK-1、MMP-3、TNF-α和IL-6的表达及治疗前后水平变化［J］.现代免疫学，2020，40(4):300-305.
［12］许甜甜，沈炳香，李向阳，等.强直性脊柱炎的中药使用规律浅析［J］.风湿病与关节炎，2020，9(4):20-23，37.
［13］庞红梅.寒湿痹颗粒治疗类风湿关节炎、强直性脊柱炎和膝骨关节炎中医辨证属寒湿痹阻证的临床疗效［J］.中医临床研究，2014，6(26):87-88.
［14］陈育尧，佟丽，吴启富，等.寒湿痹片对类风湿性关节炎模型大鼠踝关节组织病理改变的影响［J］.浙江中西医结合杂志，2010，20(1):12-14.
［15］杜望磊，李治琴，杨西超，等.白芍总苷治疗强直性脊柱炎临床疗效及对血清炎性因子水平的影响［J］.解放军医药杂志，2019，31(1):87-91.
［16］赵亚男.组蛋白甲基化酶EZH2调控强直性脊柱炎Th17分化及中药干预机制［D］.北京：中国中医科学院，2018.
［17］谭希.补肾强督治偻方有效成分分析以及对IL-23/Th17炎症轴的影响［D］.广州：广州中医药大学，2018.
［18］靳国强，赵蕾，韩宗昌，等.顽痹清丸联合常规西药治疗湿热痹阻证强直性脊柱炎28例临床观察［J］.风湿病与关节炎，2019，8(7):8-12.
［19］刘碧燕.针灸联合常规药物治疗强直性脊柱炎患者的效果［J］.中国当代医药，2019，26(2):21-24，33.
［20］伍伟，何东初.中药熏蒸联合常规西药治疗强直性脊柱炎30例临床观察［J］.风湿病与关节炎，2019，8(12):13-16.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金项目（81774349）
更新日期/Last Update: 2022-02-10